Back to Journals » Drug, Healthcare and Patient Safety » Volume 3

Prevalence and factors associated with off-label antidepressant prescriptions for insomnia

Authors Lai L, Tan, Lai

Published 8 July 2011 Volume 2011:3 Pages 27—36


Review by Single-blind

Peer reviewer comments 2

L Leanne Lai¹, Mooi Heong Tan¹, Yen Chi Lai²
¹Department of Sociobehavioral and Administrative Pharmacy, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA; ²Department of Internal Medicine, Golen Hospital, Pintong City, Taiwan

Background: The primary objective of our study was to investigate the prevalence of off-label antidepressant drug use in insomnia. The secondary objective was to compare prescribing patterns between off-label antidepressants vs hypnotics approved by the US Food and Drug Administration for insomnia, with particular emphasis on socioeconomic characteristics of patients and physicians.
Methods: We undertook a secondary data analysis using the national longitudinal database from the 2006 National Ambulatory Medical Care Survey. Subjects were identified from outpatient visits in which at least one insomnia drug was prescribed. A series of weighted Chi-squared statistics was used to compare drug use for insomnia across various patient and physician characteristics. Multivariate logistic regression was conducted to identify factors associated with off-label antidepressant drug use.
Results: Among 901.95 million outpatient visits that took place in the US in 2006, an estimated 30.43 million visits included at least one drug prescription for insomnia. Off-label antidepressants were prescribed significantly more frequently (45.1%) than nonbenzodiazepine z-hypnotics (43.2%) and benzodiazepines (11.7%). Insomnia prescribing patterns were significantly influenced by physician specialty and physician office settings. Pediatricians (odds ratio [OR]: 65.892; 95% confidence interval [CI]: 5.536–810.564) and neurologists (OR: 4.784; 95% CI: 2.044–11.201) were more likely to prescribe off-label antidepressants than psychiatrists. Self-paying patients were more likely to receive off-label antidepressants as treatment for insomnia than patients with private insurance (OR 2.594; 95% CI: 1.128–5.967).
Conclusion: Our findings indicate significant socioeconomic disparities in the use of off-label antidepressants. Future studies might explore interventional and educational strategies to ensure well informed clinical decisions that can withstand pharmaceutical marketing strategies and diagnostic uncertainties regarding the treatment of insomnia.

Keywords: insomnia, off-label drug use, antidepressants, National Ambulatory Medical Care Survey

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

Stefanini FR, Maia M, Falabella P, Pfister M, Niemeyer M, Kashani AH, Humayun MS, Koss MJ

Clinical Ophthalmology 2014, 8:847-856

Published Date: 6 May 2014

Pharmacists’ knowledge and attitudes about natural health products: a mixed-methods study

Kheir N, Gad HY, Abu-Yousef SE

Drug, Healthcare and Patient Safety 2014, 6:7-14

Published Date: 30 January 2014

Oral available agents in the treatment of RRMS

Aupérin T

Drug, Healthcare and Patient Safety 2013, 5:199-201

Published Date: 29 October 2013

Non-small cell lung cancer therapy: safety and efficacy in the elderly

Glotzer OS, Fabian T, Chandra A, Bakhos CT

Drug, Healthcare and Patient Safety 2013, 5:113-121

Published Date: 22 April 2013

Should benefit–risk assessment have its own drug “label”?

Braithwaite RS

Drug, Healthcare and Patient Safety 2011, 3:37-41

Published Date: 3 August 2011

New developments in the treatment of optic neuritis

Thomas M Jenkins, Ahmed T Toosy

Eye and Brain 2010, 2:83-94

Published Date: 18 June 2010

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis

Marcus D. Köller

Core Evidence 2007, 2:0-0

Published Date: 15 September 2007